Nathan A. Brown


Akin Gump Strauss Hauer & Feld LLP

Nathan Brown focuses his practice on food and drug law and health care reimbursement and regulatory issues. He has served in prominent roles at the U.S. Food and Drug Administration (FDA) and advises manufacturers and developers of medical devices and diagnostics, drugs and biologics, and other industry participants regulated by the FDA. Reach him at [email protected].

Recently by Nathan A. Brown


Steady Hands to Navigate the FDA's Balance of Innovation and Safety

Nathan Brown and Howard Sklamberg bring their experience at the Food and Drug Administration to bear when counseling Akin Gump clients on pre- and post-market compliance issues and more.

Read More


Amid Much Uncertainty, Hope for Medtech Innovation: New Administration and Congress positioned to drive innovation in medical technology

It seems clear that great changes for healthcare in general and medical innovation in particular are in the offing with the new administration. But whether those changes will be beneficial or detrimental – let alone cataclysmic – is anyone’s guess. Akin Gump healthcare specialists...

Read More


Regulation in the Medical Device Industry: FDA insider lays out the issues

MCC: During your tenure at the FDA, there was a strong focus on medical product safety. What prompted such attention? Brown: Over the course of my time at the FDA in a couple different capacities starting in 2010, the issue of medical product safety, including medical device safety, was a...

Read More